Treatment foot ulcers

Direct laser-assisted myocardial revascularization (DMR) is an approved technique in the US, Europe, and parts of Asia to create numerous myocardial channels. This results in the induction of a massive inflammatory reaction, which in turn induces angiogenesis. The other FDA-approved pro-angiogenic therapy is the use of recombinant human platelet-derived growth factor (Regranex) for use in the treatment of diabetic neuropathic foot ulcer s. 

The pathogenesis of diabetic foot infection stems from three key factors neuropathy, angiopathy, and immunopathy. Aerobic gram-positive cocci, such as S. aureus and P-hemolytic streptococci, are the predominant pathogens in acutely infected diabetic foot ulcers. However, chronically infected wounds are subject to polymicrobial infection and require treatment with broad-spectrum antibiotics. 

The nonpharmacologic treatment of diabetic foot ulcers may include off-loading, chemical or surgical debridement of necrotic tissue, wound dressings, hyperbaric oxygen, vascular or orthopedic surgery, and the use of human skin equivalents.30... 

Claudication and nonhealing foot ulcers are common in type 2 DM. Smoking cessation, correction of dyslipidemia, and antiplatelet therapy are important treatment strategies. 

Platelet-derived growth factor treatment of diabetic foot ulcers March 2002... 

Exercise is an essential yet neglected aspect of treatment for type 2 diabetes especially in its early stages where insulin resistance may predominate. Accumulation of at least 30 0 minutes of moderate physical activity on most days of the week is recommended. For type 1 diabetes the emphasis must be on adjusting the therapeutic regimen to allow safe sports participation to prevent precipitation of ketoacidosis or hypoglycaemia. Extra care is required in cases with known complications like proliferative retinopathy, nephropathy, foot ulcers and cardiac or peripheral vascular disease. 

The patient is diagnosed with hyperosmolar non-ketotic (HONK) syndrome secondary to infection of a diabetic foot ulcer and the treatment plan is as follows ... 

Cavanagh PR, Lipsky BA, Bradbury AW and Botek G (2005) Treatment for diabetic foot ulcers. Lancet 366(9498) 1725-1735. 

Claudication and nonhealing foot ulcers are common in type 2 DM patients. Smoking cessation, correction of lipid abnormalities, and antiplatelet therapy are important strategies in treating claudicants. Pentoxifylline or cilostazol may he useful in selected patients. Revascularization is successful in selected patients. Local debridement and appropriate footwear and foot care are vitally important in the early treatment of foot lesions. In more advanced lesions, topical treatments may be of benefit. Diabetic foot care is an excellent example of the adage, an ounce of prevention is worth a pound of cure. ... 

Martin adds the fact that Coley s Toxins were effective in treating patients having foot ulcers and a gangrenous condition, with symptoms of cold feet and lack of a pulse in the lower leg. Conducted by a Dr. Harry Gray at a Veterans Administration Hospital in the 1930s, amputation was avoided. This treatment is presumed to be effective for diabetic patients with foot ulcers. It is further noted that, at the present, physician Glen Wilcoxson, M.D., of Spanish Fort, Alabama, is treating patients with Coley s Toxins. 

Using plasma-generated NO for local treatment of ulcerous and necrotic tissues in patients with diabetes (diabetic foot ulcer) has been demonstrated by Shulutko, Antropova, and Kryuger (2004). Patients were selected for this study following 2 months of unsuccessful... 

Veves A, Sheehan P, Pham HT. A randomized, controlled trial of Promogran (a collagen/oxidized regenerated cellulose dressing) vs standard treatment in the management of diabetic foot ulcers. Arch Surg 2002 137 822-827. 

An infected foot ulcer precedes approximately 60% of lower limb amputations in the diabetic population [13], thus the rapid and appropriate treatment of soft tissue infection is paramount. There is substantial evidence suggesting that people with diabetes are more susceptible to infection due to altered immune-response [14]. Polymorphonuclear neutrophil oxidative burst activity is thought to be reduced in addition to decreased bacterial killing... 

Kruse, I. and Edelman, S. (2006). Evaluation and treatment of diabetic foot ulcers. Clin. Diabetes 24, 91-93. 

A 68-year-old male patient with a diabetic foot ulcer was treated with a combination of Vivamel alginate dressings and medical honey from the tube. Prior to Vivamel treatment the patient was dealing with the unhealed wound after amputation for more than... 

Figure 4.2 Treatment of diabetic foot ulcer with Vivamel alginate dressings coated with medical chestnut honey and Vivamel medical chestnut honey from the tube (male patient,...

Zerm, R., 2013. Local treatment of chronic wounds in patients with peripheral vascular disease, chronic venous insufficiency and diabetes topical honey for diabetic foot ulcers. Deutsches Arzteblatt International 110 (21), 373. 

L.I.F. Moura, A.M.A. Dias, E. Carvalhoa, H.C. de Sousa, Recent advances on the development of wound dressings for diabetic foot ulcer treatment—a review, Biomaterialia 9 (2013) 7093-7114. 

Lu, D., Chen, B., Liang, Z., Deng, W., Jiang, Y., Li, S., Xu, J., Wu, Q., Zhang, Z., Xie, B., Chen, S. Comparison of hone marrow mesenchymal stem cells with hone marrow-derived mononuclear cells for treatment of diabetic critical hmh ischemia and foot ulcer A douhle-hUnd, randomized, controlled trial. Diahetes Research And Clinical Practice 92, 26—36 (2011)... 

Zaulyanov L, KirsnerRS. A review of a bi-layered living cell treatment (Apligraf ) in the treatment of venous leg ulcers and diabetic foot ulcers. Clin Interv Aging 2007 2 93-8. 

Brem H, Young J, Tomic-Canic M, Isaacs C, Ehrlich HP. Clinical efficacy and mechanism of bUayered living human skin equivalent (HSE) in treatment of diabetic foot ulcers. Surg Technol Int 2003 11 23-31. 

---